KR870003998A - 퀴나졸린 유도체류의 제조방법 - Google Patents

퀴나졸린 유도체류의 제조방법 Download PDF

Info

Publication number
KR870003998A
KR870003998A KR1019860008374A KR860008374A KR870003998A KR 870003998 A KR870003998 A KR 870003998A KR 1019860008374 A KR1019860008374 A KR 1019860008374A KR 860008374 A KR860008374 A KR 860008374A KR 870003998 A KR870003998 A KR 870003998A
Authority
KR
South Korea
Prior art keywords
formula
alkyl
salt
compound
carboxy
Prior art date
Application number
KR1019860008374A
Other languages
English (en)
Other versions
KR940007270B1 (en
Inventor
하시모토 마사시
오쿠 테루오
이토 요시쿠니
나미끼 타카유끼
사와다 코조
카사하라 치요시
바바 유끼히사
Original Assignee
후지사와 토모기찌로
후지사와 야구힝 고교 가부시끼 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후지사와 토모기찌로, 후지사와 야구힝 고교 가부시끼 가이샤 filed Critical 후지사와 토모기찌로
Publication of KR870003998A publication Critical patent/KR870003998A/ko
Application granted granted Critical
Publication of KR940007270B1 publication Critical patent/KR940007270B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

퀴나졸린 유도체류의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. (a) 다음 구조식(Ⅱ)의 화합물 또는 이들의 염을 다음 구조식(Ⅲ)의 화합물 또는 이들의 염과 반응시켜 다음 구조식(Ⅰ)화합물 또는 이들의 염을 얻거나 또는 (b) 다음 구조식(Ⅳ)의 화합물 또는 이들의 염을 다음 구조식(Ⅴ)의 화합물 또는 이들의 염과 반응시켜 다음 구조식(Ⅰ)화합물 또는 이들의 염을 얻거나 또는 (c) 다음 구조식(XVI)의 화합물 또느 이들의 염을 다음 구조식(XII)의 화합물과 반응시켜 다음 구조식(Ⅰ)화합물 또는 이들의 염을 얻거나 또는 (d) 다음 구조식(Ⅰ-b) 화합물을 가수분해시켜 다음 구조식(Ⅰ-a)화합물 또는 이들의 염을 얻는 것으로 구성되는 것을 특징으로 하는 다음 구조식(Ⅰ)의 화합물 또는 이들의 염을 제조하는 방법.
    상기식에서, R1과 R3는 수소, 할로겐, 저급알콕시 또는 할로(저급)알킬, R3는 둘다 하나 또는 다수 적합한 치환체를 갖을 수 있는 아릴 또는 아릴(저급)알킬, 또는 헤테로 사이클릭(저급)알킬이며 R4는 카르복시 또는 보호된 카르복시, A는 산소 또는 황원자 Y는 카르보닐, 티오카르보닐 또는 설포닐 이고 Z는 저급 알킬렌, X는 이탈 그룹, Ra 4는 보호된 카르복시이다.
  2. 다음 구조식(Ⅱ)화합물 또는 이들의 염을 다음 구조식(Ⅲ)화합물 또는 이들의 염과 반응시켜 다음구조식(Ⅰ)화합물 또는 이들의 염을 제조하는 방법.
    상기식에서, R1와 R2는 각기 수소, 할로겐, 저급알콕시 또는 할로(저급)알킬, R3는 둘다 하나 또는 다수 적합한 치환체를 갖을 수 있는 아릴 또는 아르(저급)알킬, 또는 헤테로사이클릭(저급)알킬, R4는 카르복시 또는 보호된 카르복시, A는 산소 또는 황원자, Y는 카르보닐, 티오카르보닐 또는 설포닐,Z는 저급 알킬렌이고X는 이탈 그룹이다.
  3. 다음 구조식(Ⅳ)화합물 또는 이들의 염을 다음 구조식(Ⅴ)화합물 또는 이들의 염과 반응시켜 다음 구조식(Ⅰ)화합물 또는 이들의 염을 제조하는 방법.
    상기식에서, R1와 R2는 각기 수소, 할로겐, 저급알콕시 또는 할로(저급)알킬, R3는 둘다 하나 또는 다수 적합한 치환체를 갖을 수 있는 알킬 또는 아르(저급)알킬, 또는 헤테로사이클릭(저급)알킬, R4는 카르복시 또는 보호된 카르복시, A는 산소 또는 황원자, Y는 카르보닐, 티오카르보닐 또는 설포닐, Z는 저급 알킬렌이고 X는 이탈그룹이다.
  4. 다음 구조식(XVI)화합물 또는 이들을 염을 다음 구조식(XⅡ)화합물 또는 이들의 염과 반응시켜 다음 구조식(Ⅰ)화합물 또는 이들의 염을 제조하는 방법.
    상기식에서, R1와 R2는 각기 수소, 할로겐, 저급알콕시 또는 할로(저급)알킬, R3는 둘다 하나 또는 다수 치환체를 갖을 수 있는 아릴 또는 아르(저급)알킬, 또는 헤테로사이클릭(저급)알킬, R4는 카르복시 또는 보호된 카르복시, A는 산소 또는 황원자이고 Y는 카르보닐, 티오 카르보닐 또는 설포닐 이고 Z는 저급 알킬렌이다.
  5. 다음 구조식(1-a)화합물을 가수분해시켜 다음 구조식(Ⅰ-b)화합물 또는 이들의 염을 제조하는 방법.
    상기식에서, R1과 R2는 각기 수소, 할로겐, 저급알콕시 또는 할로(저급)알킬, R3는 둘다 하나 또는 다수치환체를 갖을 수 있는 아릴 또는 아르(저급)알킬, 또는 헤테로사이클릭(저급)알킬, A는 산소 또는 황원자, Y는 카르보닐, 티오카르보닐 또는 설포닐, Z는 저급 알킬렌이고 Ra 4는 보호된 카르복시이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR86008374A 1985-10-07 1986-10-07 Quinazoline derivatives KR940007270B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858524663A GB8524663D0 (en) 1985-10-07 1985-10-07 Quinazoline derivatives
GB8524663 1985-10-07

Publications (2)

Publication Number Publication Date
KR870003998A true KR870003998A (ko) 1987-05-06
KR940007270B1 KR940007270B1 (en) 1994-08-12

Family

ID=10586291

Family Applications (1)

Application Number Title Priority Date Filing Date
KR86008374A KR940007270B1 (en) 1985-10-07 1986-10-07 Quinazoline derivatives

Country Status (23)

Country Link
US (2) US4734419A (ko)
EP (1) EP0218999B1 (ko)
JP (3) JPS6296476A (ko)
KR (1) KR940007270B1 (ko)
CN (1) CN1017242B (ko)
AT (1) ATE60761T1 (ko)
AU (1) AU596611B2 (ko)
CA (1) CA1289139C (ko)
DE (1) DE3677452D1 (ko)
DK (1) DK158838C (ko)
ES (1) ES2021266B3 (ko)
FI (1) FI90234C (ko)
GB (1) GB8524663D0 (ko)
GR (1) GR3001502T3 (ko)
HK (1) HK6993A (ko)
HU (1) HU196972B (ko)
IE (1) IE59309B1 (ko)
IL (1) IL80213A (ko)
NO (1) NO171785C (ko)
SG (1) SG112092G (ko)
SU (1) SU1588283A3 (ko)
UA (1) UA5562A1 (ko)
ZA (1) ZA867043B (ko)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
MX7829A (es) * 1986-08-21 1993-08-01 Pfizer Quinazolindionas y piridopirimindionas y procedimiento para su preparacion
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
US4931440A (en) * 1987-07-29 1990-06-05 Fujisawa Pharmaceutical Company, Ltd. Uricosuric composition
US4898867A (en) * 1987-09-16 1990-02-06 Taiho Pharmaceutical Company, Limited Thienopyrimidine derivaties as aldose-reductase inhibitors
JP2621460B2 (ja) * 1988-02-29 1997-06-18 藤沢薬品工業株式会社 利尿または降圧剤
US5324747A (en) * 1992-07-15 1994-06-28 Hoffmann-La Roche Inc. N-substituted anilines, inhibitors of phospholipases A2
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
EP0847382B1 (de) * 1995-08-31 2000-12-20 Clariant GmbH Monoester der carboxymethylenanthranilsäuren und verfahren zu ihrer herstellung
DE19532052C2 (de) * 1995-08-31 1998-11-19 Clariant Gmbh Verfahren zur Herstellung von Chinazolinderivaten
DE69614986T2 (de) * 1995-12-26 2002-04-25 Sumitomo Chemical Co., Ltd. Verfahren zur Herstellung von Isatosäureanhydriden
US6201121B1 (en) 1995-12-28 2001-03-13 Fuji Chemical Industry Co., Ltd. Process for the preparation of 3-dihalobenzyl-2,4-quinazolinedione derivatives
US5780628A (en) * 1996-02-01 1998-07-14 Sumitomo Chemical Company, Limited Process for producing dioxoquinazolines
DE19650975A1 (de) * 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
HUP0000838A3 (en) * 1997-04-15 2001-04-28 Csir Extract containing steroid-glucosid, process for its isolation and synthesis, pharmaceutical composition containing it having appetite suppressant activity
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
IL137128A0 (en) * 1998-01-30 2001-07-24 R Tech Ueno Ltd Ophthalmic compositions containing tetrahydroquinazoline derivatives
AU2129500A (en) * 1999-01-25 2000-08-07 Fujisawa Pharmaceutical Co., Ltd. Eye drops
WO2000048447A2 (en) * 1999-02-18 2000-08-24 R-Tech Ueno, Ltd. Composition for treatment of external secretion disorders except hypolacrimation
HUP0200231A3 (en) * 1999-03-09 2002-12-28 Fujisawa Pharmaceutical Co Process for producing quinazoline derivatives or salts thereof
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
GB2355657B (en) * 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
PL365378A1 (en) 2000-11-30 2005-01-10 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
WO2002098462A1 (fr) * 2001-06-01 2002-12-12 Ono Pharmaceutical Co., Ltd. Remedes contenant un inhibiteur d'aldose reductase en tant qu'agent actif destines a des troubles de demyelinisation ou des troubles associes a la demyelinisation
JP2005529076A (ja) * 2002-02-15 2005-09-29 サイトキネティクス・インコーポレーテッド キナゾリノンの合成
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
MXPA04011074A (es) * 2002-05-09 2005-06-08 Cytokinetics Inc Compuestos de pirimidinona, composiciones y metodos.
AU2003290507A1 (en) * 2002-05-10 2004-04-08 Cytokinetics, Inc. Compounds, compositions and methods
EP1513820A4 (en) * 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
AU2003236527A1 (en) * 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
US7211580B2 (en) * 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
JP2005536553A (ja) * 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2004034972A2 (en) * 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
US20050197327A1 (en) * 2003-11-03 2005-09-08 Gustave Bergnes Compounds, compositions, and methods
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
US7439254B2 (en) * 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
DK2394983T3 (en) * 2006-07-19 2014-12-15 Du Pont Process for the preparation of 3-substituted 2-amino-5- halobenzamider
US8877717B2 (en) 2007-03-12 2014-11-04 Zadec Aps Anti-diabetic extract of rooibos
US8273746B2 (en) * 2007-03-23 2012-09-25 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors
CN101784515A (zh) * 2007-08-03 2010-07-21 弗·哈夫曼-拉罗切有限公司 作为taar1配体的吡啶甲酰胺和苯甲酰胺衍生物
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
CN102219759B (zh) * 2010-04-16 2013-07-24 中国科学院上海药物研究所 芳基甲酰胺类化合物及其制备方法、药物组合物和用途
EP2654749B1 (en) 2010-12-23 2017-05-10 The Board of Regents of The University of Texas System Methods for treating copd
WO2014182951A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
EP2994139B1 (en) 2013-05-10 2019-04-10 Gilead Apollo, LLC Acc inhibitors and uses thereof
JP6417401B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
WO2019165195A1 (en) 2018-02-22 2019-08-29 Srivastava Satish Combination therapy for the treatment of cancer
CN111499616B (zh) * 2020-05-07 2022-07-22 盐城工学院 一种芳杂环取代的喹唑啉酮衍生物及其合成方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1491510A (en) * 1973-12-14 1977-11-09 Hisamitsu Pharmaceutical Co 1-nitrophenylquinazoline-2,4(1h,3h)-diones
DE2652144A1 (de) * 1976-11-16 1978-05-18 Merck Patent Gmbh Neue chinazolindione
CA1161036A (en) * 1980-05-15 1984-01-24 Masayuki Ishikawa Quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
EP0040793B1 (en) * 1980-05-22 1985-08-28 Masayuki Ishikawa Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
JPS58159480A (ja) * 1982-03-17 1983-09-21 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
DD232702A1 (de) * 1982-09-20 1986-02-05 Adw Ddr Verfahren zur herstellung von 1,2,3,4-tetrahydrochinazolin-2,4-dion-essigsaeuren, deren salzen und estern
US4490374A (en) * 1982-09-30 1984-12-25 Ortho Pharmaceutical Corporation 5,6-Dialkoxy-3,4-optionally substituted-2(1H)quinazolinones, composition and method of use
JPS59186963A (ja) * 1983-04-08 1984-10-23 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives

Also Published As

Publication number Publication date
FI863917A0 (fi) 1986-09-29
CN86106984A (zh) 1987-05-20
HK6993A (en) 1993-02-05
CN1017242B (zh) 1992-07-01
DK158838C (da) 1991-01-14
IE59309B1 (en) 1994-02-09
JPH0482148B2 (ko) 1992-12-25
US4883800A (en) 1989-11-28
IL80213A0 (en) 1987-01-30
GB8524663D0 (en) 1985-11-13
DE3677452D1 (de) 1991-03-14
CA1289139C (en) 1991-09-17
DK158838B (da) 1990-07-23
FI90234C (fi) 1994-01-10
ATE60761T1 (de) 1991-02-15
NO171785B (no) 1993-01-25
EP0218999B1 (en) 1991-02-06
SU1588283A3 (ru) 1990-08-23
DK459086D0 (da) 1986-09-25
JPH01125322A (ja) 1989-05-17
ZA867043B (en) 1987-07-29
HUT41747A (en) 1987-05-28
ES2021266B3 (es) 1991-11-01
HU196972B (en) 1989-02-28
IE862520L (en) 1987-04-07
UA5562A1 (uk) 1994-12-28
IL80213A (en) 1991-06-30
JPH01131164A (ja) 1989-05-24
NO171785C (no) 1993-05-05
JPH05366B2 (ko) 1993-01-05
NO863980L (no) 1987-04-08
JPH0794447B2 (ja) 1995-10-11
KR940007270B1 (en) 1994-08-12
JPS6296476A (ja) 1987-05-02
SG112092G (en) 1992-12-24
NO863980D0 (no) 1986-10-06
EP0218999A2 (en) 1987-04-22
US4734419A (en) 1988-03-29
DK459086A (da) 1987-04-08
FI90234B (fi) 1993-09-30
EP0218999A3 (en) 1988-01-13
AU6358986A (en) 1987-04-09
FI863917A (fi) 1987-04-08
GR3001502T3 (en) 1992-11-23
AU596611B2 (en) 1990-05-10

Similar Documents

Publication Publication Date Title
KR870003998A (ko) 퀴나졸린 유도체류의 제조방법
KR880000433A (ko) 이미다조피리딘 및 중간체 화합물의 제조방법
KR860001793A (ko) 벤즈 이미다졸 유도체의 제조방법
KR870010005A (ko) 퀴놀린 유도체 및 그의 에스테르 또는 염의 제조법
KR860000243A (ko) 아민유도체의 제조방법
KR860000248A (ko) N-아실 산성 아미노산 디아미드 유도체의 제조방법
KR850004585A (ko) 신규 아미노과니딘 유도체의 제조방법
KR910016695A (ko) 4-(아미노메틸) 피페리딘 유도체, 그의 제조방법 및 치료에의 이용
KR890011904A (ko) 안드로스타-1,4, -디엔-3,17-디온의 6-메틸렌 유도체 합성방법
KR840001555A (ko) 치환된 2-페닐-2-(피리딜욕시)-에틸아민과 그의 등 배전자화합물 및 그들의 산부가염을 제조하는 방법
KR840001577A (ko) 복소환식 화합물의 제조방법
KR910016689A (ko) 우레아 유도체 및 이의 염, 이를 함유하는 약제학적 조성물 및 이의 제조방법
KR850004959A (ko) 아릴옥시-n-(아미노알킬)-1-피롤리딘 및 피페리딘 카복스 아미드 및 카보티오 아미드의 제조방법
KR840006226A (ko) 티아트리아진 유도체의 제조방법
KR850002979A (ko) 1,2,3-트리티안화합물의 신규 제조방법
KR850006407A (ko) 2-아릴이미다조[4,5,-c] 피리딘의 제조방법
KR930000504A (ko) 2-피페리디닐 피리미딘-4-카르복시아미드 유도체의 제법 및 치료에의 이용
KR870008838A (ko) 아릴술폰 화합물 제조방법
KR850004760A (ko) 이미다조 퀴놀린 유도체의 제조방법
SE8300432D0 (sv) Reaktiva kanelsyraderivat for framstellning av biologiskt aktiva amider
KR870002118A (ko) 벤질아민 유도체 및 그 제조방법
KR860006461A (ko) 항알레르기 작용을 갖는 화합물의 제조방법
ATE17851T1 (de) Imidazolylkarbonsaeure, deren derivate und herstellung.
KR840004105A (ko) N,n- 치환된 아졸 카복스 아미드 유도체의 제조방법
KR860007215A (ko) 벤조아미드 유도체의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20010801

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee